drug discovery drug discovery in the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. more recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. after sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. hits from these screens are then tested in cells and then in animals for efficacy. modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. once a compound that fulfills all of these requirements has been identified, the process of drug development can continue. if successful, clinical trials are developed. modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. in 2010, the research and development cost of each new molecular entity was about us$1.8 billion. in the 21st century, basic discovery research is funded primarily by governments and by philanthropic organizations, while late-stage development is funded primarily by pharmaceutical companies or venture capitalists. to be allowed to come to market, drugs must undergo several successful phases of clinical trials, and pass through a new drug approval process, called the new drug application in the united states. discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances. history the idea that the effect of a drug in the human body is mediated by specific interactions of the drug molecule with biological macromolecules, (proteins or nucleic acids in most cases) led scientists to the conclusion that individual chemicals are required for the biological activity of the drug. this made for the beginning of the modern era in pharmacology, as pure chemicals, instead of crude extracts of medicinal plants, became the standard drugs. examples of drug compounds isolated from crude preparations are morphine, the active agent in opium, and digoxin, a heart stimulant originating from digitalis lanata. organic chemistry also led to the synthesis of many of the natural products isolated from biological sources. historically, substances, whether crude extracts or purified chemicals, were screened for biological activity without knowledge of the biological target. only after an active substance was identified was an effort made to identify the target. this approach is known as classical pharmacology, forward pharmacology, or phenotypic drug discovery. later, small molecules were synthesized to specifically target a known physiological/pathological pathway, avoiding the mass screening of banks of stored compounds. this led to great success, such as the work of gertrude elion and george h. hitchings on purine metabolism, the work of james black on beta blockers and cimetidine, and the discovery of statins by akira endo. another champion of the approach of developing chemical analogues of known active substances was sir david jack at allen and hanbury's, later glaxo, who pioneered the first inhaled selective beta2-adrenergic agonist for asthma, the first inhaled steroid for asthma, ranitidine as a successor to cimetidine, and supported the development of the triptans. gertrude elion, working mostly with a group of fewer than 50 people on purine analogues, contributed to the discovery of the first anti-viral; the first immunosuppressant (azathioprine) that allowed human organ transplantation; the first drug to induce remission of childhood leukemia; pivotal anti-cancer treatments; an anti-malarial; an anti-bacterial; and a treatment for gout. cloning of human proteins made possible the screening of large libraries of compounds against specific targets thought to be linked to specific diseases. this approach is known as reverse pharmacology and is the most frequently used approach today. in the 2020s, qubit and quantum computing starter to be used to severely reduce the time needed to drug discovery. targets a "target" is produced within the pharmaceutical industry. generally, the "target" is the naturally existing cellular or molecular structure involved in the pathology of interest where the drug-in-development is meant to act. however, the distinction between a "new" and "established" target can be made without a full understanding of just what a "target" is. this distinction is typically made by pharmaceutical companies engaged in the discovery and development of therapeutics. in an estimate from 2011, 435 human genome products were identified as therapeutic drug targets of fda-approved drugs. "established targets" are those for which there is a good scientific understanding, supported by a lengthy publication history, of both how the target functions in normal physiology and how it is involved in human pathology. this does not imply that the mechanism of action of drugs that are thought to act through a particular established target is fully understood. rather, "established" relates directly to the amount of background information available on a target, in particular functional information. in general, "new targets" are all those targets that are not "established targets" but which have been or are the subject of drug discovery efforts. the majority of targets selected for drug discovery efforts are proteins, such as g-protein-coupled receptors (gpcrs) and protein kinases. screening and design the process of finding a new drug against a chosen target for a particular disease usually involves high-throughput screening (hts), wherein large libraries of chemicals are tested for their ability to modify the target. for example, if the target is a novel gpcr, compounds will be screened for their ability to inhibit or stimulate that receptor (see antagonist and agonist): if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase. another function of hts is to show how selective the compounds are for the chosen target, as one wants to find a molecule which will interfere with only the chosen target, but not other, related targets. to this end, other screening runs will be made to see whether the "hits" against the chosen target will interfere with other related targets – this is the process of cross-screening. cross-screening is useful because the more unrelated targets a compound hits, the more likely that off-target toxicity will occur with that compound once it reaches the clinic. it is unlikely that a perfect drug candidate will emerge from these early screening runs. one of the first steps is to screen for compounds that are unlikely to be developed into drugs; for example compounds that are hits in almost every assay, classified by medicinal chemists as "pan-assay interference compounds", are removed at this stage, if they were not already removed from the chemical library. it is often observed that several compounds are found to have some degree of activity, and if these compounds share common chemical features, one or more pharmacophores can then be developed. at this point, medicinal chemists will attempt to use structure–activity relationships (sar) to improve certain features of the lead compound: increase activity against the chosen target reduce activity against unrelated targets improve the druglikeness or adme properties of the molecule. this process will require several iterative screening runs, during which, it is hoped, the properties of the new molecular entities will improve, and allow the favoured compounds to go forward to in vitro and in vivo testing for activity in the disease model of choice. amongst the physicochemical properties associated with drug absorption include ionization (pka), and solubility; permeability can be determined by pampa and caco-2. pampa is attractive as an early screen due to the low consumption of drug and the low cost compared to tests such as caco-2, gastrointestinal tract (git) and blood–brain barrier (bbb) with which there is a high correlation. a range of parameters can be used to assess the quality of a compound, or a series of compounds, as proposed in the lipinski's rule of five. such parameters include calculated properties such as clogp to estimate lipophilicity, molecular weight, polar surface area and measured properties, such as potency, in-vitro measurement of enzymatic clearance etc. some descriptors such as ligand efficiency (le) and lipophilic efficiency (lipe) combine such parameters to assess druglikeness. while hts is a commonly used method for novel drug discovery, it is not the only method. it is often possible to start from a molecule which already has some of the desired properties. such a molecule might be extracted from a natural product or even be a drug on the market which could be improved upon (so-called "me too" drugs). other methods, such as virtual high throughput screening, where screening is done using computer-generated models and attempting to "dock" virtual libraries to a target, are also often used. another method for drug discovery is de novo drug design, in which a prediction is made of the sorts of chemicals that might (e.g.) fit into an active site of the target enzyme. for example, virtual screening and computer-aided drug design are often used to identify new chemical moieties that may interact with a target protein. molecular modelling and molecular dynamics simulations can be used as a guide to improve the potency and properties of new drug leads. there is also a paradigm shift in the drug discovery community to shift away from hts, which is expensive and may only cover limited chemical space, to the screening of smaller libraries (maximum a few thousand compounds). these include fragment-based lead discovery (fbdd) and protein-directed dynamic combinatorial chemistry. the ligands in these approaches are usually much smaller, and they bind to the target protein with weaker binding affinity than hits that are identified from hts. further modifications through organic synthesis into lead compounds are often required. such modifications are often guided by protein x-ray crystallography of the protein-fragment complex. the advantages of these approaches are that they allow more efficient screening and the compound library, although small, typically covers a large chemical space when compared to hts. phenotypic screens have also provided new chemical starting points in drug discovery. a variety of models have been used including yeast, zebrafish, worms, immortalized cell lines, primary cell lines, patient-derived cell lines and whole animal models. these screens are designed to find compounds which reverse a disease phenotype such as death, protein aggregation, mutant protein expression, or cell proliferation as examples in a more holistic cell model or organism. smaller screening sets are often used for these screens, especially when the models are expensive or time-consuming to run. in many cases, the exact mechanism of action of hits from these screens is unknown and may require extensive target deconvolution experiments to ascertain. the growth of the field of chemoproteomics has provided numerous strategies to identify drug targets in these cases. once a lead compound series has been established with sufficient target potency and selectivity and favourable drug-like properties, one or two compounds will then be proposed for drug development. the best of these is generally called the lead compound, while the other will be designated as the "backup". these decisions are generally supported by computational modelling innovations. some of the main computational techniques used in drug development. computational techniques play an important role in drug development by helping to identify potential drug candidates, predict their properties, and optimize their design. nature as source main article: bioprospecting traditionally, many drugs and other chemicals with biological activity have been discovered by studying chemicals that organisms create to affect the activity of other organisms for survival. despite the rise of combinatorial chemistry as an integral part of